Cargando…

Characterization of zolbetuximab in pancreatic cancer models

In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Türeci, Ӧzlem, Mitnacht-Kraus, Rita, Wöll, Stefan, Yamada, Tomohiro, Sahin, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287799/ https://www.ncbi.nlm.nih.gov/pubmed/30546962 http://dx.doi.org/10.1080/2162402X.2018.1523096

Ejemplares similares

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
por: Türeci, O, et al.
Publicado: (2019)

COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review
por: Fergie, Jaime, et al.
Publicado: (2022)

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Dangerous Liaisons: Caspase-11 and Reactive Oxygen Species Crosstalk in Pathogen Elimination
por: Roberts, JoAnn Simone, et al.
Publicado: (2015)

Racing for a SARS‐CoV‐2 vaccine
por: Türeci, Özlem, et al.
Publicado: (2021)

Molecular Characterization of Virus-induced Autoantibody Responses
por: Ludewig, Burkhard, et al.
Publicado: (2004)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation
por: Roldán, Diana Barea, et al.
Publicado: (2020)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

Selective activation of tumor growth-promoting Ca(2+ )channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2
por: Koslowski, Michael, et al.
Publicado: (2009)

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
por: Stadler, Christiane R., et al.
Publicado: (2015)

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells
por: Wagner, Meike, et al.
Publicado: (2013)

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
por: Simon, Adrian Georg, et al.
Publicado: (2023)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer
por: Salomon, Nadja, et al.
Publicado: (2021)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

mRNA therapeutics in cancer immunotherapy
por: Beck, Jan D., et al.
Publicado: (2021)

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
por: Grunwitz, Christian, et al.
Publicado: (2019)

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
por: Vormehr, Mathias, et al.
Publicado: (2015)

Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials
por: Liang, Zhanpeng, et al.
Publicado: (2023)

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
por: Castle, John C, et al.
Publicado: (2014)

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity
por: Omokoko, Tana A., et al.
Publicado: (2016)

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer
por: Vormehr, Mathias, et al.
Publicado: (2020)

A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice
por: Salomon, Nadja, et al.
Publicado: (2020)

Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide
por: Schumacher, Jens, et al.
Publicado: (2018)

Targeting the tumor vasculature with engineered cystine-knot miniproteins
por: Lui, Bonny Gaby, et al.
Publicado: (2020)

rapmad: Robust analysis of peptide microarray data
por: Renard, Bernhard Y, et al.
Publicado: (2011)

Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
por: Scheithauer, Werner, et al.
Publicado: (2019)

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins
por: Beissert, Tim, et al.
Publicado: (2017)

Establishment and characterization of a novel murine model of pancreatic cancer cachexia
por: Michaelis, Katherine A., et al.
Publicado: (2017)

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
por: McLean, Gary, et al.
Publicado: (2022)

Induction and characterization of pancreatic cancer in a transgenic pig model
por: Boas, F. Edward, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ue8qtreiqh4pviiimovi21gc4r